Omniab, Inc. revenue
Omniab, Inc.'s revenue was $18.7m in fiscal 2025, down 29.3% on the year before. Since fiscal 2021 ($34.7m) it has grown at a compound -14.4% a year. Over the last twelve months it was $40.2m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| License and Milestone Revenue | $9.8M | 52.3% | ▼ 29.5% |
| Services | $7.3M | 38.9% | ▼ 39.2% |
| Royalty | $878,000 | 4.7% | ▲ 52.4% |
| X Ploration Revenue | $754,000 | 4.0% | — |
From Omniab, Inc.'s 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Omniab, Inc. | $40.2m | 90.6% | -14.7% |
| Alpha Teknova, Inc. | $43.7m | 12.3% | 3.7% |
| Rapid Micro Biosystems, Inc. | $35.2m | 16.1% | 22.5% |
| Maxcyte, Inc. | $31.1m | -13.2% | -8.6% |
| Bionano Genomics, Inc. | $30.2m | 10.0% | -1.4% |
| Champions Oncology, Inc. | $60.7m | 6.7% | 4.8% |
Compare with peers
- Alpha Teknova, Inc. revenue
- Rapid Micro Biosystems, Inc. revenue
- Maxcyte, Inc. revenue
- Bionano Genomics, Inc. revenue
- Champions Oncology, Inc. revenue
Head to head: OABI vs TKNOOABI vs RPIDMXCT vs OABIBNGO vs OABI
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies